title: Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.
abstract: We compared the laboratory and clinical findings of 179 patients with essential thrombocythemia (ET) and 77 with polycythemia vera (PV) classified according to the presence of the JAK2 V617F mutation. A gradient was observed in laboratory values between patients with JAK2 wild-type ET, JAK2 V617F ET and PV (all of whom carried the JAK2 mutation). The rate of thrombotic complications in JAK2-positive ET patients was significantly higher than that in wild-type ET patients and not statistically different from that in PV patients.
authors.forename: Guido
authors.initials: G
authors.lastname: Finazzi
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
authors.forename: Vittoria
authors.initials: V
authors.lastname: Guerini
authors.forename: Alessandra
authors.initials: A
authors.lastname: Carobbo
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011087:Polycythemia Vera / Q000150:complications* / Q000235:genetics*; D012306:Risk; D013921:Thrombocytopenia / Q000150:complications* / Q000235:genetics*; D013927:Thrombosis / Q000150:complications* / Q000235:genetics* / Q000473:pathology*
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2